Cytek Biosciences, Inc.

Listed Company

CTKBCIK 0001831915NasdaqAcceleratedLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$201.49M

Net Income

$-66.54M

Total Assets

$461.54M

Equity

$341.74M

Shares Out

129.14M

Op. Cash Flow

$-4.69M

CTKB$4.63+40.30% · past yearDBEQ Basic

Daily closing prices

Business

Cytek Biosciences is a leading cell analysis solutions company that develops compact, high-performance flow cytometry and cell sorting instruments using its proprietary Full Spectrum Profiling (FSP) technology. The company offers the Cytek Aurora, Northern Lights, and Aurora Evo analyzer systems; Aurora CS cell sorter; imaging flow cytometers under the Amnis brand; and entry-level Guava and Muse analyzers, all supported by proprietary software, reagents, and services. Products are distributed globally to pharmaceutical companies, biopharma firms, academic research centers, contract research organizations, and clinical laboratories through direct sales and distributor networks.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue, net	201	200	193	164	128
Total cost of sales	97	89	84	63	49
Gross profit	104	111	109	101	79
Research and development	36	39	44	35	24
Sales and marketing	49	49	49	33	25
General and administrative	59	43	44	35	21
Total operating expenses	145	132	137	103	70
Loss from operations	−40	−21	−28	−2	9
Interest income (expense), net (Notes 11, 12)	−474,000	5	−2	−3	—
Interest income	2	5	6	5	49,000
Other income, net	9	4	8	1	−2
Total other income, net	11	15	12	3	−3
Loss before income taxes	−30	−6	−16	1	6
Provision for (benefit from) income taxes	37	320,000	−4	−1	3
Net loss	−67	−6	−12	2	3
Less: net loss allocated to noncontrolling interests	0	0	0	92,000	−26,000
Net loss attributable to common stockholders, basic	−67	−6	−12	3	0
Net loss attributable to common stockholders, diluted	−67	−6	−12	3	0
Net loss attributable to common stockholders per share, basic (in dollars per share)	−0.52	−0.05	−0.09	0.02	0
Net loss attributable to common stockholders per share, diluted (in dollars per share)	−0.52	−0.05	−0.09	0.02	0
Weighted-average shares used in calculating net loss per share, basic (in shares)	128	131	135	135	77
Weighted-average shares used in calculating net loss per share, diluted (in shares)	128	131	135	139	82
Foreign currency translation adjustment, net of tax	2	1	−549,000	−2	832,000
Unrealized gain (loss) on marketable securities	58,000	97,000	−29,000	17,000	0
Net comprehensive loss	−64	−5	−13	890,000	4

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	91	99	167	297	365
Restricted cash	0	29,000	331,000	3	0
Marketable securities	171	179	95	45	0
Trade accounts receivable, net	63	61	56	49	30
Inventories	48	44	61	48	32
Prepaid expenses and other current assets	20	14	13	13	5
Total current assets	392	396	392	454	432
Deferred income tax assets, noncurrent	0	33	30	20	9
Property and equipment, net	18	18	18	14	6
Operating lease right-of-use assets	11	10	11	14	15
Goodwill	17	17	16	10	10
Intangible assets, net	17	20	23	4	5
Other noncurrent assets	7	5	3	3	2
Total assets	462	500	494	519	463
Trade accounts payable	6	6	3	5	3
Legal settlement liability, current	2	2	3	2	1
Accrued expenses	23	21	20	21	15
Other current liabilities	17	13	8	8	6
Deferred revenue, current	29	25	23	13	7
Total current liabilities	78	68	56	49	33
Legal settlement liability, noncurrent	7	9	16	16	14
Deferred revenue, noncurrent	18	16	15	13	10
Operating lease liability, noncurrent	14	8	9	12	0
Long term debt	525,000	1	2	2	0
Other noncurrent liabilities	2	2	2	2	1
Total liabilities	120	104	101	94	58
Commitments and contingencies (Note 18)	—	—	—	—	—
Common stock, $0.001 par value; 1,000,000,000 authorized shares as of December 31, 2025 and December 31, 2024, respectively; 128,550,136 and 129,205,901 issued and outstanding shares as of December 31, 2025 and December 31, 2024, respectively.	129,000	129,000	131,000	135,000	126,000
Additional paid-in capital	441	431	423	443	424
Accumulated deficit	−102	−35	−29	−17	−20
Accumulated other comprehensive income	2	16,000	−1	−697,000	897,000
Total stockholders equity	342	396	393	426	405
Total liabilities and stockholders equity	462	500	494	519	463

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	8	7	6	2	1
Amortization of operating lease-right-of use assets	4	3	3	3	0
Provision for (benefit from) credit losses	413,000	−64,000	269,000	—	—
Stock-based compensation	25	27	22	17	7
Loss on disposal of property and equipment	415,000	55,000	7,000	0	0
Provision for excess and obsolete inventory	2	2	1	756,000	488,000
Deferred income taxes	34	−3	0	0	—
Gain on investments, accretion, and amortization, net	−6	−5	−7	—	—
Interest expenses for accretion of the legal settlement liabilities	−328,000	−7	2	2	2
Trade accounts receivable	368,000	−5	−7	−20	−12
Inventories	−5	15	4	−18	−7
Prepaid expenses and other assets	−3	−3	−10	−19	−6
Trade accounts payable	448,000	3	−2	2	−256,000
Accrued expenses and other liabilities	4	−817,000	729,000	7	11
Legal settlement liabilities	−1	−1	−298,000	373,000	−4
Deferred revenue	4	4	7	9	10
Lease liabilities	−4	−3	−3	−2	0
Net cash provided by (used in) operating activities	−5	25	5	−12	5
Purchases of marketable securities	−278	−274	−176	−44	0
Maturities of marketable securities	292	195	132	0	0
Purchase of property and equipment	−4	−4	−5	−10	−4
Proceeds from sales of property and equipment	252,000	288,000	0	0	—
Acquisition of business	0	−471,000	−45	0	−17
Purchase of intangible assets (patents)	−106,000	−204,000	−179,000	−120,000	0
Payment for additional investment in Cytek Japan, net of cash acquired	0	0	−236,000	0	371,000
Net cash provided by (used in) investing activities	10	−83	−94	−56	−21
Proceeds from line of credit	6	4	0	0	—
Payment for repurchase of shares	−15	−22	−44	0	0
Repayment of loan	−5	−557,000	−565,000	−50,000	0
Proceeds from Employee Stock Purchase Plan	1	2	2	—	—
Payments for taxes related to net share settlement of equity awards	−670,000	−554,000	−419,000	−209,000	0
Proceeds from issuance of common stock under employee stock plans	325,000	1	1	1	642,000
Net cash used in financing activities	−13	−16	−42	6	214
Effect of exchange rate changes on cash, cash equivalents and restricted cash	109,000	5	−1	−2	1
Net decrease in cash, cash equivalents and restricted cash	−8	−69	−132	−65	198
Cash paid for taxes, net of refunds	2	4	5	10	3
Fixed asset purchases in accounts payable at period end	129,000	177,000	40,000	67,000	134,000
Intangible asset in accrued expenses at period end	26,000	0	510,000	30,000	93,000
Accrued excise taxes for share repurchase	0	0	320,000	0	0
Derecognition of right-of-use assets	0	205,000	0	0	—
Transfer of inventory to property and equipment	122,000	0	0	—	—
Operating Lease Right-of-use assets obtained in exchange for operating lease liabilities	5	3	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Cytek Biosciences, Inc.'s CIK number?

Cytek Biosciences, Inc.'s SEC CIK number is 0001831915 (1831915). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Cytek Biosciences, Inc.'s SEC filings?

All of Cytek Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Cytek Biosciences, Inc. last report earnings?

Cytek Biosciences, Inc. (CTKB) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211948). This is Cytek Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Cytek Biosciences, Inc.'s most recent earnings 8-K?

Cytek Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211948. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Cytek Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →